



DÉFI SOCIÉTAL SANTÉ, CHANGEMENT DÉMOGRAPHIQUE ET BIEN-ÊTRE



**Wébinaire d'information
Appels à Projets 2020**

**Priorité 1 : Médecine Personnalisée
Priorité 5: Décoder le rôle de l'environnement, dont le
changement climatique, pour la santé et le bien-être**

pcn-sante@recherche.gouv.fr

Structure du programme de travail 2018-2020

Call 1. Better Health and care, economic growth and sustainable health systems,

1.1 Personalised medicine

1.2 Innovative health and care industry

1.3 Infectious diseases and improving global health

1.4. Innovative health and care systems - Integration of care

1.5 Decoding the role of the environment for health and well-being

1.6 Contribution to the Call on Digital transformation in Health and Care



Call 2. – Digital transformation in Health and Care



Call 3. – Trusted digital solutions and Cyber security in Health and Care



Sommaire



RAPPEL SUR LES REGLES DE PARTICIPATION

- Règles d'éligibilité
- Coopération Internationale
- Brexit
- Budget



PRESENTATION DES APPELS A PROJETS

Priority 1: Personalized Medicine

BHC-06-2020: Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data

HCO-01-2020: Actions in support of the International Consortium for Personalised Medicine


HCO-03-2020: Bridging the divide in health research and innovation – boosting return on investment

HCO-17-2020: Coordinating and supporting research on the human microbiome in Europe and Beyond


Priority 2 : Decoding the role of environment including climate change, for health and well-being

BHC-36-2020: Micro- and nano-plastics in our environment: Understanding exposures and impacts on human health

RECHERCHE DE PARTENAIRES



Règles de participation



Consortium: Minimum 3 entités légales de 3 Etats-membres ou Etats associés différents

Toute entité légale peut participer

Entités légales financées : établies dans les Etats-membres ou Etats associés

A noter : Exception unique au défi santé : les entités des USA sont financées

Cas spécifique de la Grande-Bretagne

Pour les Etats tiers : Certains pays sont financés (voir liste) – ou leur participation est expressément prévue dans le programme de travail



Coopération Internationale : Politique de la CE



Toutes les lignes d'appel sont ouvertes à la coopération internationale



Contribution financière de la C.E pour le Défi Santé :

28 Etats-Membres, 16 Etats-Associés, 124 Pays-Tiers et USA



Pour les autres Pays-Tiers, pas de financement de la CE

→ Mécanismes de co-financement existants pour certain pays: Australie, Brésil, Canada, Chine, Honk-Kong&Macau, Inde, Japon, Corée, Mexique, Russie, Taiwan




Certaines lignes d'appel ciblent des pays spécifiques

Participation des pays tiers cités obligatoires pour que le projet soit éligibles

- Stimuler la coopération dans un domaine spécifique qui représente un fardeau à la fois pour l'Union Européenne et le(s) pays ciblé(s)
- Donner un « signe » visible de coopération (diplomatie scientifique)

BREXIT & H2020




Accord de retrait conclu au 31.10.19

- ✓ « Business as usual »
- ✓ UK pleinement éligible jusqu'à la fin d'H2020 (y compris pour les appels ouverts/clos après mars 2019)
- ✓ Tous les projets H2020 financés jusqu'à leur terme


« No deal »

- × Eligibilité des consortiums peut être remise en question (3 entités établies dans 3 Etats Membres ou Etats Associés différents)
- × UK non éligible aux actions individuelles (ERC, EIC et certaines actions MSCA)
- ✓ Financement de la participation des entités britanniques au travers d'un fonds dédié

Défi Santé : Budget



1948 Md€ pour WP 18-20



Structure du programme de travail 2018-2020

Call 1. Better Health and care, economic growth and sustainable health systems, (13 RIA, 10 CSA, 1PCP, 1PPI)

- 1.1 Personalised medicine
- 1.2 Innovative health and care industry
- 1.3 Infectious diseases and improving global health
- 1.4. Innovative health and care systems - Integration of care
- 1.5 Decoding the role of the environment for health and well-being
- 1.6 Contribution to the Call on Digital transformation in Health and Care

Budget 2020
498 M€



DG RTD

Call 2. – Digital transformation in Health and Care (4 RIA, 4 CSA)

Budget 2020
92 M€




DG CNECT

Call 3. – Trusted digital solutions and Cyber security in Health and Care (2 RIA)

Budget 2020
70 M€



Différents types d'actions



RIA - Research and Innovation Actions

→ recherche fondamentale et appliquée, développement et l'intégration de technologie, essais et validation d'un prototype à petite échelle dans un laboratoire ou un environnement simulé

Taux de financement européen 100% et durée habituelle 36-60 mois

IA - Innovation Actions

→ prototypage, essais, démonstration ou pilotes, validation du produit à grande échelle, première commercialisation. Les projets peuvent inclure des activités limitées de recherche et de développement

Taux de financement européen 70% (sauf pour les entités à but non lucratif qui sont financées à 100% de leurs coûts totaux éligibles) et durée habituelle 30-36 mois


CSA - Coordination and Support Actions

→ études de design pour de nouvelles infrastructures, activités complémentaires de planning stratégique, mise en réseau et la coordination entre programmes dans différents pays


Taux de financement européen 100% et durée habituelle 12-30 mois

Différents types d'actions

- **PCP**: développement d'une solution innovante, en collaboration avec les fournisseurs, répondant à un besoin qui ne peut pas être pourvu par le marché
Le Taux de financement dépend de chaque appel, jusqu'à 90% maximum
- **PPI**: achat de solution innovante déjà commercialisée
Le taux de financement dépend de chaque appel, jusqu'à 50% maximum



Structure du programme de travail 2018-2020



CALENDRIER 2019-2020

Derniers appels du programme cadre Horizon 2020

Publication officielle du programme de travail 2020 : **2 juillet 2019**

Dates limites de soumission des dossiers

- **DG RTD**
 - **24 Septembre 2019** : dépôt des dossiers de première étape (pour les appels en 2 étapes)
 - **07 Avril 2020** : dépôt des projets complets pour les appels en 2 étapes et en 1 étape
- **DG CNECT** : tous les appels sont en 1 seule étape
- **13 Novembre 2019**: 3 appels (HCC-06-2020, HCC-07-2020 et DT-TDS-05-2020)
- **22 avril 2020**: tous les autres appels



TYPES D'APPEL


- 16 RIA (Research and Innovation Action), dont 4 en deux étapes (**SC1-BHC-08-2020, SC1-BHC-24-2020, SC1-BHC-29-2020, SC1-DTH-13-2020**)
- 14 CSA (Coordination and Support Action), dont 3 ERA-NET

Part des CSA très importante dans ce Work Programme

→ préfiguration des prochains appels à projets ?

La France doit être impliquée dans ces activités

Priority 1 – Personalised medicine



OBJECTIF:

- Délivrer des soins personnalisés au bénéfice des patients et des citoyens grâce à la génération de connaissance sur l'étiologie des maladies et leur traduction en innovation technologique.
- Comprendre l'impact économique et le potentiel de la médecine personnalisée pour transformer les systèmes de soins

CIBLE:

maladies complexes, microbiome humain, maladies rares et échanges de données pour la médecine personnalisée, modèles économiques, renforcer les collaborations internationales et régionales

CONTEXTE POLITIQUE:


[Council conclusions on Personalised Medicine](#)

[International Consortium on Personalised Medicine](#)

[Action Plan ICPeMed](#)

[European Reference Networks](#)

BHC-06-2020: Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data



Budget total: 40 M€

- ❖ 8 à 15 M€ par projet
- ❖ 2 à 5 projets financés
- ❖ Type d'action: RIA

7 avril 2020


Dépôt en 1 étape



SPECIFIC CHALLENGE:

- The availability of appropriate decision support tools for healthcare practitioners can promote **uptake of personalised medicine in health care**.
- Need to carry out **research activities aiming to develop and validate such decision tools** that would integrate available and/or emerging diagnostic means for the area concerned,
- On-going progress in the fields of bioinformatics and biostatistics, advanced analytical tools (e.g. machine learning) up to Artificial Intelligence (AI) solutions, should make possible the development of devices, platforms or novel approaches leading to highly personalised diagnosis
- Ultimate result would be a **detailed health status assessment from a multitude of viewpoints**, in a systemic way and easy to use for clinical purposes, leading to better diagnostic accuracy, increased effectiveness and efficiency of treatments.
- Novel hardware enabling truly innovative, integrative diagnostic platforms can also be consider

BHC-06-2020: Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data



Budget total: 40 M€

- ❖ 8 à 15 M€ par projet
- ❖ 2 à 5 projets financés
- ❖ Type d'action: RIA

7 avril 2020


Dépôt en 1 étape



SCOPE

- Develop **tools, platforms or services** that will use information provided by most relevant diagnostic means for a particular area → assessment of the health status in a patient.
- **Integrate various data sources** such as medical records, in vitro and/or in vivo diagnostics, medical imaging, -omics data, functional tests (lab-on-a-chip) etc
- Take into account the **actual needs of healthcare practitioners**
- **Test and validation in real-life settings** in pilot centres, facilitating future Health Technology Assessment.
- Contribute to **improving diagnosis and clinical decision**, not only integrate existing data, and should involve **intelligent human-computer interface** solutions to facilitate its daily use in clinical practice.

BHC-06-2020: Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data



Budget total: 40 M€

- ❖ 8 à 15 M€ par projet
- ❖ 2 à 5 projets financés
- ❖ Type d'action: RIA

7 avril 2020


Dépôt en 1 étape



EXPECTED IMPACT:

- Increase EU's capacity to innovate in the area of medical instruments technologies through the **development of new diagnostic tools, platforms or services integrating various diagnostic data** and providing quick, detailed, accurate and highly **personalised diagnostics for optimal decision in clinical practice.**
- **Improve the quality and sustainability of healthcare** systems through quicker and more encompassing diagnosis of medical conditions, leading to quicker and better clinical decisions and timely delivery of effective personalised treatments, with reduction of errors and delays (and costs associated to them).
- Contribute to the **growth of the European diagnostics sector, in particular for SMEs.**
- Reinforce EU's role among world leaders in the production of medical diagnostic devices

BHC-06-2020: Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data



Budget total: 40 M€

- ❖ 8 à 15 M€ par projet
- ❖ 2 à 5 projets financés
- ❖ Type d'action: RIA

7 avril 2020


Dépôt en 1 étape

Analyse
du PCN

COMMENTAIRES

- Le projet peut proposer un « hardware », un « software », une plateforme, etc ... Il n'y a aucune prescription sur le format de l'outil
- Il est possible d'intégrer toutes les données pertinentes pour le domaine étudié, il n'est pas obligatoire d'intégrer toutes les données décrites dans le texte, elles sont citées seulement à titre d'exemple
- L'objectif est de l'amener le plus proche possible du marché, viser un niveau TRL élevé
- Il est important d'impliquer des PME dans le projet

BHC-06-2020: Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data



Data

CONTEXTE POLITIQUE EUROPEEN

Council conclusions on Personalised Medicine

International Consortium on Personalised Medicine

Action Plan ICPeMed



A.7 Research projects to develop innovative decision support tools for healthcare providers

Progress towards personalised medicine relies fundamentally upon data and information on current diagnosis and treatment options. On the one hand, all healthcare providers should support ongoing research efforts with their knowledge and data. On the other hand, they also need suitable and easy handling support tools based on the latest ICT developments and research results. Only then can their decision-making be supported and if possible optimised, considering the latest personalised medicine improvements. Not only will citizens and patients benefit, but economic aspects can also be considered, for example, if non-responders should receive the respective drugs, or if multi-medication can be reduced or avoided.

BHC-06-2020: Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data

EXEMPLES DE PROJETS DÉJÀ FINANCES

Work Programme 2014-2015: Development of new diagnostic tools

PHC 10 – 2014: Development of new diagnostic tools and technologies: in vitro devices, assays and platforms

48M€, 9 projects funded

PHC 11 – 2015: Development of new diagnostic tools and technologies: in vivo medical imaging technologies

49M€, 8 projects funded

PHC 12 – 2014/2015: Clinical research for the validation of biomarkers and/or diagnostic medical devices


→ SME Instrument, 111 M€, 77 projects funded

PHC 26 – 2014: Self-management of health and disease: citizen engagement and mHealth

59,6M€, 14 projects funded

PHC 27 – 2015: Self-management of health and disease and patient empowerment supported by ICT

15M€, 3 projects funded



BHC-06-2020: Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data

EXEMPLES DE PROJETS DÉJÀ FINANCES

Work Programme 2014-2015: Development of new diagnostic tools




Work Programme 2016-2017 : Standardisation (CSA)

SC1-HCO-02-2016: Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine

1 project funded

SC1-PM-03-2017: Diagnostic characterisation of rare diseases

2 projects funded



BHC-06-2020: Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data

EXEMPLES DE PROJETS DÉJÀ FINANCES

[Work Programme 2014-2015: Development of new diagnostic tools](#)



[Work Programme 2016-2017 : Standardisation \(CSA\)](#)




[Work Programme 2017-2018 : Integration of Data and increase in TRL](#)


SC1-BHC-10-2019: *Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis**

SC1-BHC-20B-2020: *Public procurement of innovative solutions (PPI) for diagnostics for infectious diseases*

SC1-DTH-07-2018: *Exploiting the full potential of in-silico medicine research for personalised diagnostics and therapies in cloud-based environments*



HCO-01-2020: Actions in support of the International Consortium for Personalised Medicine



Budget total: 4 M€

- ❖ 1,5 à 2M€ par projet
- ❖ 2 projets financés
- ❖ Type d'action: CSA

7 avril 2020


Dépôt en 1 étape



SPECIFIC CHALLENGE:

- Personalised Medicine is a very broad and multifaceted area where success relies on a well-functioning **collaboration between several disciplines** and **different actors**.
- While great advances have been made in some fields of medicine, in particular **in stratification of cancer patients** and in **addressing rare diseases**, most of today's healthcare protocols do not include personalised approaches apart from occasional division into broad age groups (children/adults/elderly), sex or ethnicity.
- As is the case for a relatively nascent field there is a need for **standardisation of approaches**, including for sampling, data storage, interpretation and data exchange and also for clinical trials design and reimbursement models.
- Many **needs for coordination and support activities have been identified by ICPeMed**, an EU Member States led initiative which includes representatives from most EU countries along with several other European countries, Brazil and Canada (secretariat oct 20 20)
- **Wider internationalisation of ICPeMed** can be underpinned by coordinating **networking activities with third countries**

HCO-01-2020: Actions in support of the International Consortium for Personalised Medicine



Budget total: 4 M€

- ❖ 1,5 à 2M€ par projet
- ❖ 2 projets financés
- ❖ Type d'action: CSA

7 avril 2020

Dépôt en 1 étape

SCOPE Each action should focus on **one of the following fields**

1-International aspect:

The action should focus on building links with **third countries** by analysing the **potential and advantages of collaboration in personalised medicine (PM) with those countries**, studying areas of interest for Europe in PM collaboration and promoting international standards in the field

The project should focus on **countries in Africa**. **Alignment with activities** of the Global Alliance for Chronic Diseases (**GACD**) and The European and Developing Countries Clinical Trials Partnership (**EDCTP**) activities should be explored


The project should have a duration of at least **four years** and address sustainability beyond that to ensure longer term structuring effect.

2-ICPerMed secretariat: The project **should continue the work done by the secretariat for ICPerMed**, e.g. maintenance of existing services, organising the meetings of the ICPerMed Executive Committee, convening dedicated workshops and preparing and issuing updates of the ICPerMed Action Plan. Furthermore maintaining the network of policy makers and funders gathered in

ICPerMed and expanding the membership to new interested and complementary partners as well as maintaining communication with all EC funded activities related to ICPerMed.



HCO-01-2020: Actions in support of the International Consortium for Personalised Medicine



Budget total: 4 M€

- ❖ 1,5 à 2M€ par projet
- ❖ 2 projets financés
- ❖ Type d'action: CSA

7 avril 2020

Dépôt en 1 étape

EXPECTED IMPACT

International aspect:


Integrating the country/group of countries into ICPeMed activities.

Support wider adoption of standards developed in Europe. Support the EU-AU policy dialogues relevant to research and health (2020 call). Contribute towards the UN Sustainable Development Goal 3: Ensure healthy lives and promote well-being for all at all ages.

ICPeMed secretariat (2020 Call): Ensure **continuity of the operations of ICPeMed** beyond 2020. **Increase the visibility of the consortium** and ensure openness of the structure. Provide **harmonised vision for the further development of personalised medicine**. Contribute to the convergence of members' approaches to personalised medicine and further alignment of research efforts in the field.



HCO-01-2020: Actions in support of the International Consortium for Personalised Medicine



Analyse
du PCN

COMMENTAIRES

In the past, actions supported on health economy, regional cooperation within Europe, Era-Net, international cooperation with CELAC and China,

→ This year: cooperation with AFRICA (whole of Africa is addressed)

Objective: Involve the African countries in the policy dialogue of personalized medicine

HCO-01-2020: Actions in support of the International Consortium for Personalised Medicine

Analyse
du PCN


EXEMPLES DE PROJETS DÉJÀ FINANCES en 2018

Acronyme	titre	coord	Part FR
HEcoPerMed	Healthcare- and pharma-economic models in support of the International Consortium for Personalised Medicine	AT	-
SAPHIRE	Securing Adoption of Personalised Health in REgions	BE	-
EULAC-PerMed	Widening EU-CELAC policy and research cooperation in Personalised Medicine	ES	ECRIN
REGIONS4PERMED	INTERREGIONAL COORDINATION FOR A FAST AND DEEP UP TAKE OF PERSONALISED HEALTH	IT	-

EXEMPLES DE PROJETS DÉJÀ FINANCES en 2019

IC2PerMed	Integrating China in the International Consortium for Personalised Medicine	IT	Inno TSD
PERMIT	PERsonalised MedicIne Trials	FR/ ECRIN	Univ Paris- Descartes
SINO-EU-PerMed	Widening Sino-EU policy and research cooperation in Personalised Medicine	DE	-

HCO-03-2020: Bridging the divide in health research and innovation – boosting return on investment



Budget total: 2 M€

- ❖ 1,5 à 2M€ par projet
- ❖ 1 projet financé
- ❖ Type d'action: CSA

7 avril 2020

Dépôt en 1 étape



SPECIFIC CHALLENGE:


The Innovation Union Scoreboard reveals significant **disparities in terms of research and innovation performance among the different member states and regions** within the European Union. The disparities are equally present in health research and innovation which unfortunately **also translates into lower participation in the Union's research and innovation framework programme, Horizon 2020.**

There are serious efforts deployed at national and European level to help to close the R&I divide. Many instruments provide direct investment to organisations from lagging regions and countries, such as the **European Structural and Investment Funds, national grants, the Spreading Excellence and Widening Participation programme of Horizon2020 while others encourage networking such as the COST actions.**

These European and national investments yield the most when beneficiaries have the necessary capabilities, adequate governance structure, and suitable science and HR policies

This call aims **providing support in the health R&I domain to organisations from lower performing regions that are willing to carry out structural reforms to improve their R&I performance.** The call builds on past efforts of the European Commission (especially the HCO-14 2014 and the HCO-08 2017 calls in H2020 SC1).

HCO-03-2020: Bridging the divide in health research and innovation – boosting return on investment



Budget total: 2 M€

- ❖ 1,5 à 2M€ par projet
- ❖ 1 projet financé
- ❖ Type d'action: CSA

7 avril 2020

Dépôt en 1 étape



SCOPE


Applicants should propose actions that would shift benefiting organisations' R&I performance and would eventually **increase their participation in EU funded collaborative projects.**

Proposed activities should **aim to strengthen research development; improve governance, managerial and administration practices; increase the organisations' international profile; develop HR policies to attract and retain talents**, taking into account gender aspects; and create a culture that rewards scientific performance and innovation. Applicants may propose any actions that contribute towards these goals.

Beneficiaries of the activities should be active in the field of health research and innovation and should come from low performing Member States/regions that have identified health R&I as a priority in their Research and Innovation Strategies for Smart Specialisation (RIS3).

Applicants shall seek **synergies** with European Structural and Investment Funds, with European and national research and innovation programmes and if applicable with EEA and Norway grants. Applicants are encouraged to leverage funding of this call with other resources.

HCO-03-2020: Bridging the divide in health research and innovation – boosting return on investment



Budget total: 2 M€

- ❖ 1,5 à 2M€ par projet
- ❖ 1 projet financé
- ❖ Type d'action: CSA

7 avril 2020

Dépôt en 1 étape


EXPECTED IMPACTS

An increased number of organisations from low performing Member States/regions among the top international health R&I institute that are able to attract funding and talents and render these resources into scientific excellence and innovation.

Ultimately, **increased participation rate of low performing countries in the EU's Research and Innovation Framework Programme**



HCO-03-2020: Bridging the divide in health research and innovation – boosting return on investment




COMMENTAIRES

- Widening section for the U13 countries (Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia)
- Make use of the lot of investment that has already been done on this matter with a health focus
- **Non widening countries can also participate**

Objective: Improve their governance; reform their institutes to have more international scientific profiles



HCO-03-2020: Bridging the divide in health research and innovation – boosting return on investment



EXEMPLE DE PROJETS DÉJÀ FINANCES:

HCO-14 2014 : Bridging the divide in European health research and innovation

-RegHealth-RI The European regions network for Health Research and Innovation

Coord Esp

-DanuBalt DanuBalt: Novel Approaches in Tackling the Health Innovation and Research Divide in the Danube and Baltic Sea Region

Coord DE


HCO-08 2017 : Actions to bridge the divide in European health research and innovation

-Alliance4Life Life Science Alliance: Closing Research and Innovation Divide in the EU

Coord : Tchéquie



HCO-17-2020: Coordinating and supporting research on the human microbiome in Europe and Beyond



Budget total: 2 M€

- ❖ 1,5 à 2 M€ par projet
- ❖ 1 projet financé
- ❖ Type d'action: CSA

7 avril 2020

Dépôt en 1 étape


SPECIFIC CHALLENGE:

Integration and application of metagenomics data from the human microbiome has shown large potential for personalised medicine approaches, although causal relationships and confounders are still largely unknown. Comparable information and details about microbiome composition and functionality in healthy citizen and patients are very valuable to complete the picture i.e. to better understand the healthy microbiome and to predict its development.

The number of European and international projects and initiatives is increasing but their results and data cannot be properly compared as they have different underlying methods, standards and operating procedures. The International Human Microbiome Consortium (IHMC) as well as other current initiatives aim to strengthen international cooperation, to increase data comparability and to agree common standards, procedures and methods. **There is a need to avoid having the same research carried out multiple times at different places and to better agree at European and at international level. This collaboration should increase coherence and data comparability to better exploit existing microbiome data and clinical information in a standardised way.**



HCO-17-2020: Coordinating and supporting research on the human microbiome in Europe and Beyond



Budget total: 2 M€

- ❖ 1,5 à 2 M€ par projet
- ❖ 1 projet financé
- ❖ Type d'action: CSA

7 avril 2020

Dépôt en 1 étape



SCOPE

Proposals should aim for **synergistic collaboration** and agreement across **various research and innovation programmes on the human microbiome**, in Europe and worldwide, dealing with **sample collection, processing, standardisation and healthy states references at different sites of the human body (not only one organ), including also interaction with omics, impact of drugs, nutritional and environmental aspects as well as sex and gender differences**. In particular, they should support the agreement of concrete references of healthy human metagenomes across various different populations.


Proposals should map the progress and the state of play for specific disease and health issues as well as the success and meaningfulness in different countries.

-They should **propose concrete and strategic research actions on the human microbiome addressing gaps, emerging fields and political priorities**.

-They should complement, support and enhance cooperation in similar activities within Europe and beyond: **International cooperation is encouraged with relevant partners from outside the EU**.

Proposals should cover the whole spectrum of human microbiome research from patient data collection all the way to study reporting in publications, social, ethical and legal aspects. Proposals should avoid networking without output and provide appropriate indicators to measure its progress and impact

HCO-17-2020: Coordinating and supporting research on the human microbiome in Europe and Beyond



Budget total: 2 M€

- ❖ 1,5 à 2 M€ par projet
- ❖ 1 projet financé
- ❖ Type d'action: CSA

7 avril 2020

Dépôt en 1 étape



EXPECTED IMPACT

-International agreement on concrete methods, standards, procedures and in vivo models. Harmonisation and increased comparability of metagenomics, metabolomics and human microbiome data in Europe and beyond.


-International agreement on definitive references of healthy human metagenomes. These references should apply across various different populations and allow end-users and citizens to see which microbiome is clinically healthy.

-More meaningful results through collaborative synergistic collection of microbiome data from different directions. Improved coherence and reduction of overlap between national, EU and other funding in the area of human microbiome research, thus ensuring an efficient use of the available human and financial resources.

- Knowledge exchange and enhanced engagement of citizens, scientists and political stakeholders for priority health risks. Validated results will be delivered faster to people.

-Integration of metagenomics and human microbiome references into other multilateral co-operation areas or personalised medicine approaches.

HCO-17-2020: Coordinating and supporting research on the human microbiome in Europe and Beyond



Budget total: M€

- ❖ 1,5 à 2 M€ par projet
- ❖ 1 projet financé
- ❖ Type d'action: CSA

7 avril 2020

Dépôt en 1 étape

Analyse
du PCN

COMMENTAIRES


- Lot of breakthrough research the last five years, on personalised prevention particularly.

→ standardise and harmonise all data generated on the microbiome, procedures and samples collection

Proposals should take into account other relevant European and international research and networking initiatives as well as “one health initiatives”.

Impact: Guidelines or agreement on standards and methods, increase comparability between different microbiome data

Priority 5 – Decoding the role of the environment, including climate change, for health and well-being



OBJECTIF:

- Améliorer l'évaluation du risque de l'environnement sur la santé et le bien-être, et les impacts socio-économiques associés
- Développer des mesures de mitigations

CIBLE: Nouvelles méthodes de test et de screening pour l'identification de produits chimiques perturbateurs endocriniens, développement d'un « exposome humain » (pour permettre l'évaluation tout au long de la vie de l'influence environnementale sur les individus) et l'établissement de priorités pour un nouvel agenda de recherche

CONTEXTE POLITIQUE:



The 7th Environment Action Programme (EAP)



WHO Environment and Health Process (since 1989)




The UNFCCC Paris Agreement



REACH and EU related policies

BHC-36-2020: Micro- and nano-plastics in our environment: Understanding exposures and impacts on human health



Budget total: 25 M€

- ❖ 4 à 6 M€ par projet
- ❖ 4 à 6 projets financés
- ❖ Type d'action: RIA

7 avril 2020


Dépôt en 1 étape



SPECIFIC CHALLENGE

- A significant proportion of the **plastic produced is not disposed of properly and persists in the environment**, especially the marine environment. Plastic products can be slowly degraded into smaller pieces (micro-or even nanoplastics).
- Plastic debris is associated with a “**cocktail of contaminants**” made up of chemical ingredients present originally in the plastic and chemical pollutants adsorbed to the plastic from the environment, including metals and other persistent contaminants such as polychlorinated biphenyls (PCBs) and flame retardants.
- Risk assessments and reviews carried out in recent years have concluded that there is evidence that **humans are exposed to micro-and nano-plastics** through their diet, drinking water or inhalation.
- Understanding of the fate and toxicity of these plastic particles in humans constitutes a major knowledge gap, rendering it difficult to **carry out proper science-based risk assessment and management**.

BHC-36-2020: Micro- and nano-plastics in our environment: Understanding exposures and impacts on human health



Budget total: 25 M€

- ❖ 4 à 6 M€ par projet
- ❖ 4 à 6 projets financés
- ❖ Type d'action: RIA

7 avril 2020

Dépôt en 1 étape




SCOPE

Innovative approaches to provide policy relevant scientific data for improved human health hazard and risk assessment of micro- and/or nano-plastics.

12 Research priorities to be considered

- Environmental sources and transmission to human
- Identification and quantification
- Exposure levels and methods for human biomonitoring
- Analytical methods for detection
- Microbial colonisation of micro-and/or nano-plastics as vectors for potential pathogens
- Micro-and/or nano-plastics as condensation nuclei and/or carriers for airborne particulate matter and chemicals harmful to health;
- Toxicology
- Fate of micro-and/or nano-plastics in the gastro-intestinal or respiratory tracts and secondary organs;
- Effects and transport of micro-and/or nano-plastics across biological barriers, and bioaccumulation
- Consideration of the effect of shape (as well as size) of micro-and/or nano-plastics, and comparison with the behaviour and effects of non-synthetic homologues, e.g. wool fibres;
- Immune responses;
- Preliminary investigations into long-term effects of micro-and/or nano-plastics.

BHC-36-2020: Micro- and nano-plastics in our environment: Understanding exposures and impacts on human health



Budget total: 25 M€

- ❖ 4 à 6 M€ par projet
- ❖ 4 à 6 projets financés
- ❖ Type d'action: RIA

7 avril 2020


Dépôt en 1 étape

EXPECTED IMPACTS

- Better understanding of health impacts of exposure to micro-and/or nano-plastics, including preliminary investigations into long-term impacts.
- Innovation in human health hazard and risk assessment methodologies of micro-and/or nano-plastics.
- Contribution to the health-relevant aims of the European Strategy for Plastics in a Circular Economy and of the Bioeconomy Strategy



BHC-36-2020: Micro- and nano-plastics in our environment: Understanding exposures and impacts on human health



Budget total: 25 M€

- ❖ 4 à 6 M€ par projet
- ❖ 4 à 6 projets financés
- ❖ Type d'action: RIA

7 avril 2020


Dépôt en 1 étape

Analyse
du PCN

COMMENTAIRES

- Les priorités de recherche listées dans le scope ne sont pas toutes à inclure dans un même projet (budget limité)
- D'autres thématiques non listées peuvent également être incluses dans les propositions
- Les propositions doivent impérativement prévoir un budget pour des actions conjointes avec les projets sélectionnés dans des topics liés (voir slides "related calls")
- Les propositions doivent également prévoir l'implication du JRC dans leur proposition. Pas besoin de les impliquer en tant que partenaire au stade du montage de projet. Le JRC collaborera avec toutes les propositions sélectionnées

BHC-36-2020: Micro- and nano-plastics in our environment: Understanding exposures and impacts on human health



CONTEXTE POLITIQUE EUROPEEN


- A EUROPEAN STRATEGY FOR PLASTICS IN A CIRCULAR ECONOMY :

Communication COM(2015)614 : Boucler la boucle - Un plan d'action de l'Union européenne en faveur de l'économie circulaire

Brochure : List of future EU measures to implement the Strategy ; List of measures recommended to national authorities and industry


Site de la CE : https://ec.europa.eu/commission/news/eu-plastics-strategy-2018-nov-20_en (2018)

- On 9 January 2019, the Commission's Group of Chief Scientific Advisors endorsed the SAPEA Evidence Review Report "A scientific perspective on microplastics in nature and society" and sent it to the Commission in lieu of the explanatory note which was announced in the Advisors 'Initial Statement' on this subject, July 2018.
- SAM (2018). 'Microplastic Pollution: The Policy Context - Background Paper', The Scientific Advice Mechanism Unit of the European Commission, 68 p. web version
- The European Commission's (EC) Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) published on January 14, 2019, a statement and a position paper on emerging health and environmental issues.



Analyse
du PCN

BHC-36-2020: Micro- and nano-plastics in our environment: Understanding exposures and impacts on human health



EXEMPLE DE PROJETS DÉJÀ FINANCES

Pas de topics liés au plastique dans les programmes de travail santé depuis 2014

CE-BIOTEC-04-2018: New biotechnologies for environmental remediation

CE-BIOTEC-05-2019: microorganism communities for plastics bio-degradation

HBM4EU: Coordinating and advancing human biomonitoring in Europe to provide evidence for chemical policy making



BHC-36-2020: Micro- and nano-plastics in our environment: Understanding exposures and impacts on human health

RELATED CALL FOR PROPOSALS 2020 IN OTHER PROGRAMMES

SC2 : Bioeconomy

SFS-21-2020: Emerging challenges for soil management

BG-07-2019-2020: The Future of Seas and Oceans Flagship Initiative: [C] 2020 - Technologies for observations

CE-FNR-09-2020: Pilot action for the removal of marine plastics and litter

FNR-08-2020: Supporting the food safety systems of the future

SC5: Environment

CE-SC5-24-2020: Improving the sorting, separation and recycling of composite and multi-layer materials

CE-SC5-28-2020: Develop and pilot circular systems in plastics, textiles and furniture sectors


CE-SC5-25-2020: Understanding the transition to a circular economy and its implications on the environment, economy and society

CE-SC5-29-2020: A common European framework to harmonise procedures for plastics pollution monitoring and assessments

CE-SC5-30-2020: Plastics in the environment: understanding the sources, transport and distribution of plastics pollution

LEIT


CE-BIOTEC-09-2020: Upcycling bio plastics of food and drinks packaging





Recherche de partenaires

Monter un consortium




CRITÈRES DE SÉLECTION DES PARTENAIRES

- ✓ Motivés : ils doivent contribuer à la rédaction (Work Package leader)
- ✓ Expertise scientifique nécessaire au projet: rôle précis pour chacun et complémentarité des compétences : attention à ne pas avoir 2 partenaires avec la même expertise
- ✓ Correspondre aux attentes de l'appel à projet: ne pas inclure des partenaires pour « leur faire plaisir » et ne pas négliger « oublier » des expertises attendues dans le consortium
- ✓ Si pertinent, avoir des partenaires avec lesquels vous avez déjà travaillé et pour lesquels vous pouvez démontrer une collaboration fructueuse.

Pas de nombre de partenaires idéal
→ pertinence et expertise


Les différents types de partenaires



Les appels à projets demandent des consortium multidisciplinaires, avec différents secteurs nécessaires pour atteindre l'impact attendu par la Commission Européenne


- ✓ PME
- ✓ Agences réglementaires (EMA, CNIL, ANSM...)
- ✓ Associations de patients
- ✓ Agences de Santé publique (Santé Publique France, Haute Autorité de Santé)
- ✓ Villes/Régions
- ✓ Infrastructures européennes de recherche (EATRIS, MIRRI, BBMRI, ELIXIR, ECRIN, Instruct, EuroBioImaging, ERINHA...)
- ✓ Sciences Humaines et Sociales (SHS)

Recherche de partenaires



→ Outils et méthodes à ma disposition?

- 1** J'utilise mon réseau scientifique
- 2** Je participe à des événements de networking dédiés aux appels H2020
- 3** J'identifie des projets déjà financés sur la même thématique
- 4** Je dépose mon profil sur une plateforme de recherche de partenaires / je consulte les profils déposés



1 J'utilise mon réseau scientifique

- ✓ Je contacte mes collaborateurs européens
- ✓ Je participe aux congrès scientifiques
- ✓ J'utilise les réseaux sociaux (ex: groupe LinkedIn pour IMI)

2 Je participe à des événements de networking dédiés aux appels H2020


Evènements récents passés

- ✓ 3 juillet 2019 : Infoday de la Commission Européenne, Bruxelles
(enregistrement et slides disponibles sur le site)
- ✓ 4 juillet 2019: Evènement de partenariat sur les appels santé 2020
(Présentations et participants publiés sur le site)
- ✓ 5 juillet 2019: Infoday national à Paris
(présentations disponibles sur la page de l'évènement)

Tous les événements sont disponibles sur la page du PCN :

<http://www.horizon2020.gouv.fr/pid29768/sante.html>

Recherche de partenaires



3

J'identifie des projets déjà financés sur la même thématique

Portail du participant de la CE, « Partner Search »

Ce site permet de rechercher des partenaires:

-par thématique /-par appel /-par pays

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search>


European Commission | Funding & tender opportunities
Single Electronic Data Interchange Area (SEDIA)

SEARCH FUNDING & TENDERS | HOW TO PARTICIPATE | PROJECTS & RESULTS | WORK AS AN EXPERT | SUPPORT

- Key steps
- Reference documents
- Participant register
- Partner search

Funding & tender opportunities managed by the European Commission (Single Electronic Data Interchange Area) is the er... EU bodies.

Recherche de partenaires



Search by
Involvement in EU funded programmes

Keyword

Topic

Call

Programme

Search by
Organisation details

Organisation name

Organisation type

Country

City

PIC number

[Search partners](#) [Clear filters](#)



Results: 51 [Download excel list](#)

ORGANISATION NAME	ORGANISATION TYPE	ORGANIS... STATUS	COUNTRY	CITY	#PROJEC...
ACIB GmbH	Small or medium-size enterprise	VALIDATED	Austria	GRAZ	12
EUROPEAN MOLECULAR BIOLOGY LABORATORY	International Organisation	VALIDATED	Germany	HEIDELBE...	5
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV	Non-governmental organization	VALIDATED	Germany	MUENCHEN	4
JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN	Higher or secondary education establishment	VALIDATED	Germany	FRANKFU... AM MAIN	3
Concentris Research Management GmbH	Small or medium-size enterprise	VALIDATED	Germany	Fürstenfel...	2
CHARITE - UNIVERSITAETSMEDIZIN BERLIN	Higher or secondary education establishment	VALIDATED	Germany	BERLIN	2

Higher or secondary

Possibilité de chercher des partenaires par mots-clés, par ville, par type de partenaires (PMEs, Organisation de recherche, université etc ...)

En cliquant sur une organisation, la liste des projets dans lesquels elle participe s'affiche

Recherche de partenaires


3

J'identifie des projets déjà financés sur la même thématique

Plateforme de données des projets, CORDIS

The screenshot shows the CORDIS search interface. At the top, there is the European Commission logo and the text 'CORDIS Résultats de la recherche de l'UE'. A search bar contains the text 'regenerative medicine' and a 'Recherche' button. Below the search bar, there is a navigation menu with options like 'ACCUEIL', 'RESULTS PACKS', 'MAGAZINES RESEARCH*EU', 'ACTUALITÉS ET ÉVÉNEMENTS', 'PROJETS ET RÉSULTATS', and 'À PROPOS'. A 'Connexion' button is also visible. Below the navigation menu, there are options to 'Enregistrer la recherche', 'Mes recherches enregistrées', and 'Télécharger mes résultats de recherche'. A 'Mon livret' button is also present. On the left side, there is a 'Filtres' sidebar with a 'Collection' section containing several checkboxes: 'Tout sélectionner', 'Projets' (checked), 'Results Packs', 'Magazines Research*eu', 'Résultats en bref', and 'Actualités'. The main content area shows the search results for 'regenerative medicine', indicating '180 résultats pour «regenerative medicine»'. It also shows filters for 'Collection: Projets' and 'Programme: H2020'. A 'Réinitialiser tous les filtres' button is visible. At the bottom, there is a 'Dernière mise à jour' and 'Titre' dropdown menu. The first result is 'ARISE - Aortic Valve Replacement using Individualised Regenerative Allografts: Bridging the Therapeutic Gap', which is associated with the 'HORIZON 2020' logo.

Recherche de partenaires



Filters <

- ▶ Collection
- ▶ Domain of Application
- ▶ Programme
- ▶ Topic ID ⓘ

Show all filters

Search


▼ Collection

- Select all
- Projects
- Results Packs
- Research*eu magazines
- Results in Brief
- News
- Project Deliverables
- Project Publications
- Report Summaries
- Events
- Programmes

▼ Domain of Application

- Industrial Technologies
- Fundamental Research
- Transport and Mobility
- Health
- Society
- Security
- Climate Change and Environment
- Energy
- Space
- Digital Economy
- Food and Natural Resources

Recherche de partenaires



Filters <

- ▶ Collection
- ▶ Domain of Application
- ▶ Programme
- ▼ Topic ID ⓘ

SC1-BHC-15-2018 ✕

Show all filters

Search

Edit query 

6 results found


Filtered by:

Collection: Projects

Topic ID: SC1-BHC-15-2018

✕ Clear all filters

 Last updated  Title 



TT4CL Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

ID: 815622


From: **1 May 2019** to **30 April 2023**

Cutaneous leishmaniasis (CL) is a poverty related, neglected tropical disease, which is without an effective and cheap systemic treatment. The aim of TT4CL is to develop a new orally available drug for treatment of CL aimed towards registration with stringent

Coordinated in: **United Kingdom**

Programme: **H2020-EU.3.1.3.**

Recherche de partenaires



4 Je dépose mon profil sur une plateforme de recherche de partenaires / je consulte les profils déposés




Pour tout type de partenaires

Sur le site du participant portal: profil ciblé sur un appel

Les profils sont publiés par le LEAR de votre organisme: texte de 500 signes max

Fundings & tenders opportunities/search funding &/ l'appel qui vous intéresse

Recherche de partenaires




Publish partner search for topic:

Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data (SC1-BHC-06-2020)

Partner Search list

Results: **1**

 Download excel list




Filter..

ORGANISATION NAME 

REQUEST DATE 

ORGANISATION TYPE 

COUNTRY 

EXPERTISE REQUEST OR OFFER 

ACTIONS 

AGENCIA PUBLICA EMPRESARIAL SANITARIA COSTA DEL SOL

Hospital Costa del Sol in Marbella, Malaga (Spain) is an outstanding Public Hospital attached to the Ministry of Health of the Government of Andalusia in the South of Spain. Our mission is to provide public quality health care to the citizens, seeking efficiency and optimum use of resources. Hospital Costa del Sol has 2.000 professionals and cover a population of over 470.000. We have expertise in clinical trials, epidemiological studies and health care service improvement interventions.

04-Jul-2019

Research Organisation


ES

Expertise offer



Actions

Recherche de partenaires



4 Je dépose mon profil sur une plateforme de recherche de partenaires / je consulte les profils déposés



Plateforme thématiques

Réseau Ideal-Ist pour T.I.C., Technologies de l'information et de la Communication
ICPerMed Partnering Tool: médecine personnalisée



Pour les entreprises

Je contacte le réseau **Enterprise Europe Network** <https://een.ec.europa.eu/>
base de données en ligne pour présenter les partenaires commerciaux qui sont intéressés par différents types de coopération, si elle se rapporte à des activités commerciales, techniques ou R & D.



Exemples de réseaux privés

NCURA National Council of University Research Administrators <https://www.ncura.edu/>
Vision 2020 pour collaboration avec acteurs académiques et industries <http://2020visionnetwork.eu/>
EARMA European Association of Research Managers and Administrators <http://www.earma.org/>
EARTO European association of Research and Technol Organisations <https://www.earto.eu/>
LERU League of European Research Universities <https://www.leru.org/>

Devenir Expert Evalueateur

HORIZON 2020

Pourquoi devenir expert ?

- ▶ S'approprier le mécanisme d'évaluation et affiner ses compétences en matière de rédaction de propositions ;
- ▶ Se faire connaître de la C.E. comme un expert du domaine ;
- ▶ Réaliser un état de l'art de la recherche européenne dans un secteur donné ;
- ▶ Développer un réseau de partenaires potentiels ;
- ▶ Mieux connaître les mécanismes européens ;
- ▶ Promouvoir sa perspective sur les enjeux de la recherche

Qui peut être expert ?

Peuvent prétendre à devenir experts, les individus de toute nationalité, bénéficiant d'un haut niveau d'expertise dans un domaine relatif à une thématique d'Horizon 2020, qu'ils proviennent de la sphère académique, de la recherche ou de la sphère économique et commerciale.

4 Critères de sélection des experts

- Expertise : technique, et/ou gestion de projet, et/ou innovation, et/ou exploitation, et/ou dissémination, et/ou communication, et/ou "business development"
- Diversité géographique
- Parité
- Rotation/renouvellement : 30% par an

En quoi consiste le travail d'évaluation ?

- ▶ Examiner et évaluer des propositions déposées dans le cadre des appels ;
- ▶ Travailler :
 - dans le cadre de sessions courtes d'une durée maximale de 10 jours par an ;
 - à distance et/ou à Bruxelles ou Luxembourg

Le nombre
de propositions à traiter
est variable selon
l'appel



Rémunération

Il s'agit d'une indemnité de 450 euros TTC/jour
Prise en charge des frais de mission

Déplacements à prévoir


L'expert évaluateur doit prévoir 1 semaine de travail et de déplacement à Bruxelles ou Luxembourg par campagne d'évaluation.

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/work-as-an-expert>

Webinaire d'information dédié :

✓ Devenir expert évaluateur: 15 juin 2018

Actions COST



COST : The European Cooperation in Science and Technologie

Finance la création de réseaux de recherche, offrant aux scientifiques en Europe et au-delà un espace ouvert de collaboration.

Prochain appel projet : 5 Septembre 2019, deux autres dates au printemps et automne 2020

- Bottom-up : ouvert à toutes les disciplines
- Durée de 4 ans : possibilité de rejoindre un consortium en cours
- Finance les actions de réseautage : réunions, conférences, formations, publication etc ...
- En moyenne 130 000€ par an pour des consortiums de 25 partenaires


→ Opportunités d'identifier des partenaires potentiels sur votre thématiques, rejoindre un réseau déjà formé, ou créer le votre : <https://www.cost.eu/cost-actions/browse-actions/>

→ Visibilité au niveau européen

→ Préparation d'un réseau pour un futur appel à projet

Contact Emmanuel Pasco-Viel : cost-cnc@recherche.gouv.fr

Actions COST



Recherche de réseaux existants par thématique ou par mots-clés



[News](#) [Events](#) [Multimedia](#) [Publications](#) [Contact us](#) [e-COST](#)

[Who we are](#) ▾

[Funding](#) ▾

[COST Actions](#) ▾

[Academy](#)

Browse Actions

[Home](#) > [Browse Actions](#)

Search in Title Only

[More Filters](#)

Start Date

Country

Chemistry and Molecular Sciences and Technologies

Forests, their Products and Services

Trans-Domain Proposal

Targeted Networks

COST Association

All Fields

Approval Year


Status

Active

Closed

All

Page PCN : Recherche de Partenaires




Nouvelle page dédiée à la publication d'offres et de recherche d'expertises pour des appels à projets identifiés sur le site h2020.gouv.fr

<http://www.horizon2020.gouv.fr/cid143501/recherche-de-partenaires.html>

- Publication par topics (Défi Santé, IMI) avec renvoi vers les offres publiées directement sur le participant portal
- Publication des offres de partenaires étrangers reçues *via* le réseau des PCN Européens
- Template à télécharger directement sur la page dédiée et à renvoyer à l'adresse pcn-sante@recherche.gouv.fr
- Possibilité de diffuser les offres au sein du réseau des PCN Européens

Conclusions – Ce qu’il faut retenir




La clé de la participation à H2020: la visibilité

LE RESEAU, LE RESEAU, LE RESEAU

« Un coordinateur qui veut monter un projet doit pouvoir vous identifier dans les 3 minutes qui suivent la lecture de l’appel »

Conclusions – Ce qu'il faut retenir



Horizon 2020


Le programme finance toute la chaîne de l'innovation

Défi Santé

Angle sociétal : relever les défis pour améliorer la vie des citoyens

Programme de travail 2020

Il a été officiellement publié le **2 juillet 2020**. C'est le dernier d'Horizon 2020



Anticiper

Identifier le plus tôt possible les lignes d'appel qui vous concernent

PCN Santé

Contactez le pour vérifier l'adéquation de votre projet avec la ligne d'appel ciblée

Cellule Europe

Contactez la le plus tôt possible (que vous soyez partenaire ou coordinateur)



Liste des prochains
webinaires et inscription



Appels à projets des priorités 1 et 5 - 6 Septembre 2019 à 10h - Inscription

- SC1-BHC-06-2020: Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data
- SC1-HCO-01-2020: Actions in support of the International Consortium for Personalised Medicine
- SC1-HCO-03-2020: Bridging the divide in health research and innovation – boosting return on investment
- SC1-HCO-17-2020: Coordinating and supporting research on the human microbiome in Europe and Beyond
- SC1-BHC-36-2020: Micro- and nano-plastics in our environment: Understanding exposures and impacts on human health

Appels à projets des priorités 2 et 4: 19 Septembre 2019 à 10h - Inscription

- SC1-BHC-11-2020: Advancing the safety assessment of chemicals without the use of animal testing
- SC1-HCO-18-2020: Developing methodological approaches for improved clinical investigation and evaluation of high-risk medical devices
- SC1-HCO-19-2020: Reliable and accessible information on cell and gene-based therapies
- SC1-BHC-37-2020: Towards the new generation of clinical trials – trials methodology research
- SC1-HCO-20-2020: Coordination of clinical research activities of the European Reference Networks

Appels à projets de la priorité 3: 4 Septembre à 14h - Inscription

- SC1-BHC-17-2020: Global Alliance for Chronic Diseases (GACD) – Prevention and/or early diagnosis of cancer
- SC1-BHC-20A-2020: Pre-Commercial Procurement for integrated care solutions
- SC1-BHC-20B-2020: Public Procurement of innovation solutions for diagnostics for infectious diseases
- SC1-BHC-33-2020: Addressing low vaccine uptake
- SC1-BHC-34-2020: New approaches for clinical management and prevention of resistant bacterial infections in high prevalence settings
- SC1-BHC-35-2020: Creation of a European wide sustainable network for harmonised large-scale clinical research studies for infectious disease



Appels à projets de la priorité 6- 1 (DG CNECT): 19 Septembre 2019 à 14h - Inscription

- SC1-DTH-02-2020: Personalised early risk prediction, prevention and intervention based on Artificial Intelligence and Big Data technologies
- SC1-DTH-04-2020: International cooperation in smart living environments for ageing people
- SC1-DTH-06-2020: Accelerating the uptake of computer simulations for testing medicines and medical devices
- SC1-DTH-14-2019-2020: Pre-commercial Procurement for Digital Health and Care Solutions
- SC1-HCC-07-2020: Support for European eHealth Interoperability roadmap for deployment
- SC1-HCC-08-2020: Scaling up innovation for active and healthy ageing

Appels à projets de la priorité 6- 2 (DG CNECT): 10 Septembre 2019 à 10h - Inscription

- SC1-DTH-12-2020: Use of Real-World Data to advance research on the management of complex chronic conditions
- SC1-HCC-09-2020: Supporting deployment of eHealth in low and lower middle income countries in Africa for better health outcomes
- SC1-HCC-10-2020: Towards a Health research and innovation Cloud: Capitalising on data sharing initiatives in health research
- SC1-HCC-06-2020: Coordination and Support to better data and secure cross-border digital infrastructures building on European capacities for genomics and personalised medicine
- DT-TDS-04-2020: AI for Genomics and Personalised Medicine
- DT-TDS-05-2020: AI for Health Imaging